News
The Department of Health and Human Services will cancel contracts and pull funding for some vaccines that are being developed ...
Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.
Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...
MedPage Today on MSN1d
Did FDA Pick the Wrong COVID Vaccine Strain Last Season?The researchers followed participants from October 2024 to January 2025. Median age was 76 years, and 54.2% were women. By ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...
As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...
Pfizer's Albert Bourla told investors that major drugmakers are "ready to to roll up their sleeves" and build out more direct ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Free Malaysia Today on MSN11h
Pfizer’s earnings boosted by Covid-19 products, lower expensesPfizer was among the 17 companies that received a July 31 letter from president Donald Trump demanding lower drug prices.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback